These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38765191)

  • 1. Trust performance in managing inflammatory arthritis over time in England and Wales: a latent class analysis approach.
    Yang Z; Arumalla N; Alveyn E; Gallagher S; Price E; Russell MD; Bechman K; Norton S; Galloway J
    Rheumatol Adv Pract; 2024; 8(2):rkae053. PubMed ID: 38765191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Achievement of NICE quality standards for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.
    Ledingham JM; Snowden N; Rivett A; Galloway J; Ide Z; Firth J; MacPhie E; Kandala N; Dennison EM; Rowe I
    Rheumatology (Oxford); 2017 Feb; 56(2):223-230. PubMed ID: 27694337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid evaluation of the Special Measures for Quality and challenged provider regimes: a mixed-methods study.
    Fulop NJ; Capelas Barbosa E; Hill M; Ledger J; Li Ng P; Sherlaw-Johnson C; Rolewicz L; Schlepper L; Spencer J; Tomini SM; Vindrola-Padros C; Morris S
    Health Soc Care Deliv Res; 2023 Oct; 11(19):1-139. PubMed ID: 37921786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of complementary and alternative medicines is associated with delay to initiation of disease-modifying anti-rheumatic drug therapy in early inflammatory arthritis.
    Lahiri M; Santosa A; Teoh LK; Clayton JA; Lim SY; Teng GG; Cheung PPM
    Int J Rheum Dis; 2017 May; 20(5):567-575. PubMed ID: 28524619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Worse outcomes linked to ethnicity for early inflammatory arthritis in England and Wales: a national cohort study.
    Adas MA; Norton S; Balachandran S; Alveyn E; Russell MD; Esterine T; Amlani-Hatcher P; Oyebanjo S; Lempp H; Ledingham J; Kumar K; Galloway JB; Dubey S
    Rheumatology (Oxford); 2022 Dec; 62(1):169-180. PubMed ID: 35536178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic delay is common for patients with axial spondyloarthritis: results from the National Early Inflammatory Arthritis Audit.
    Russell MD; Coath F; Yates M; Bechman K; Norton S; Galloway JB; Ledingham J; Sengupta R; Gaffney K
    Rheumatology (Oxford); 2022 Feb; 61(2):734-742. PubMed ID: 33982063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Online Patient-Reported Outcome Measure Engagement Is Dependent on Demographics and Locality: Findings From an Observational Cohort.
    Yates M; Bechman K; Adas MA; Wright H; Russell M; Nagra D; Clarke B; Ledingham J; Norton S; Galloway J
    J Rheumatol; 2023 Sep; 50(9):1178-1184. PubMed ID: 37188382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Group cognitive-behavioural programme to reduce the impact of rheumatoid arthritis fatigue: the RAFT RCT with economic and qualitative evaluations.
    Hewlett S; Almeida C; Ambler N; Blair PS; Choy E; Dures E; Hammond A; Hollingworth W; Kadir B; Kirwan J; Plummer Z; Rooke C; Thorn J; Turner N; Pollock J
    Health Technol Assess; 2019 Oct; 23(57):1-130. PubMed ID: 31601357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring the macro-level, meso-level and micro-level barriers and facilitators to the provision of good quality early inflammatory arthritis (EIA) care in England and Wales.
    Zasada M; Yates M; Ayers N; Ide Z; Norton S; Galloway J; Taylor C
    RMD Open; 2021 Aug; 7(3):. PubMed ID: 34400579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 admissions and mortality in patients with early inflammatory arthritis: results from a UK national cohort.
    Adas MA; Russell MD; Cook E; Alveyn E; Hannah J; Balachandran S; Oyebanjo S; Amlani-Hatcher P; Ledingham J; Norton S; Galloway JB
    Rheumatology (Oxford); 2023 Sep; 62(9):2979-2988. PubMed ID: 36645234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Patterns with Disease-Modifying Antirheumatic Drugs in U.S. Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis.
    Walsh JA; Pei S; Penmetsa GK; Sauer BC; Patil V; Walker JH; Clewell J; Douglas KM; Clegg DO; Cannon GW; Halwani A
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1218-1228. PubMed ID: 31663467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Financial performance of English NHS trusts and variation in clinical outcomes: a longitudinal observational study.
    Nagendran M; Kiew G; Raine R; Atun R; Maruthappu M
    BMJ Open; 2019 Jan; 9(1):e021854. PubMed ID: 30696667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy.
    Wabe N; Wojciechowski J; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Proudman S; Wiese MD
    Int J Rheum Dis; 2017 Oct; 20(10):1447-1456. PubMed ID: 28952204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries.
    Kimsey L; Weissman JS; Patel A; Drew A; Koehlmoos T; Sparks JA
    Semin Arthritis Rheum; 2019 Apr; 48(5):821-827. PubMed ID: 30190154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient- and clinician-reported outcomes for patients with new presentation of inflammatory arthritis: observations from the National Clinical Audit for Rheumatoid and Early Inflammatory Arthritis.
    Ledingham JM; Snowden N; Rivett A; Galloway J; Ide Z; Firth J; MacPhie E; Kandala N; Dennison EM; Rowe I
    Rheumatology (Oxford); 2017 Feb; 56(2):231-238. PubMed ID: 27694336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors associated with the initiation of biologic disease-modifying antirheumatic drugs in Texas Medicaid patients with rheumatoid arthritis.
    Kim G; Barner JC; Rascati K; Richards K
    J Manag Care Spec Pharm; 2015 May; 21(5):401-7. PubMed ID: 25943001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis.
    Maradit-Kremers H; Nicola PJ; Crowson CS; O'Fallon WM; Gabriel SE
    J Rheumatol; 2006 Feb; 33(2):248-55. PubMed ID: 16358365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of Baseline Transcriptomic Analysis of Rheumatoid Arthritis Synovium as an Indicator for Long-Term Clinical Outcomes.
    Anaparti V; Wiens D; O'Neil LJ; Hubbard E; Robl R; Smolik I; Hitchon C; Lipsky PE; El-Gabalawy H
    Front Med (Lausanne); 2022; 9():823244. PubMed ID: 35592852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis.
    Desai RJ; Rao JK; Hansen RA; Fang G; Maciejewski ML; Farley JF
    J Manag Care Spec Pharm; 2014 Nov; 20(11):1110-20. PubMed ID: 25351972
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.